A study of Neoadjuvant Hormone therapy in patient with Advanced Prostate Cancer Undergoing Radical Prostatectomy.

Trial Identifier: D8664C09827
Sponsor: AstraZeneca
NCTID:: NCT03971110
Start Date: January 2021
Primary Completion Date: November 2022
Study Completion Date: November 2022
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Chinese Translation

Trial Locations

Country Location
CN Beijing, CN, 100034
CN Changsha, CN, 430033
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN guangzhou, CN, 510080
CN Guangzhou, CN, 510630
CN Hangzhou, CN, 310020
CN Hangzhou, CN, 310014
CN Hefei, CN, 230022
CN Shanghai, CN, 200032
CN shenyang, CN, 110001
CN Shijiazhuang, CN, 050001
CN Urumqi, CN, 830054
CN Xi'an, CN, 710061
CN Zhengzhou, CN